{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-168644","form_type":"8-K","ticker":"WVE","cik":"0001631574","company_name":"Wave Life Sciences Ltd.","filed_at":"2025-07-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.524269+00:00","generated_at":"2026-05-17T23:03:46.805190+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Wave Life Sciences Q2 2025 net loss $50.5M; cash $208.5M; key trial data on track","bullets":["Cash $208.5M as of June 30, 2025, down from $302.1M at Dec 31, 2024; runway into 2027.","Revenue $8.7M in Q2 2025 vs $19.7M YoY; net loss $50.5M vs $32.9M YoY.","WVE-006 AATD: multidose complete in 200mg cohort; 200mg data in 3Q 2025, 400mg data fall 2025.","WVE-007 obesity: expanded Cohort 2 (240mg) to 32; data from Cohorts 1 and 2 expected 4Q 2025.","Appointed Christopher Wright, MD, PhD, as Chief Medical Officer in May 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-168644","json":"https://secwatch.observer/filing/0001193125-25-168644.json","markdown":"https://secwatch.observer/filing/0001193125-25-168644.md","text":"https://secwatch.observer/filing/0001193125-25-168644.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1631574/000119312525168644/0001193125-25-168644-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1631574/000119312525168644/d157278d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T23:03:46.805190+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}